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Abstract
Introduction
IGF-1 (insulin-like growth factor-1) is a hormone involved in cell growth and other important
processes. In the kidney, IGF-1 has a stimulating effect, increasing the blood flow and glo-
merular filtration rate. Although many experimental animal studies regarding the role of IGF-
1 in the kidney have been conducted, few human studies are available in the literature. Obe-
sity is a cause of renal failure, and several glomerular lesions associated with obesity have
been described. However, no studies regarding the levels of IGF-1 in morbidly obese
patients with renal injury associated with obesity have been conducted.
Aim
To determine the serum IGF-1 concentrations in morbidly obese patients with normal renal
function but with different types of early obesity-related glomerular lesions and to evaluate
the possible relationship between IGF-1 and the presence of renal lesions.
Methods
Eighty morbidly obese patients with renal biopsy, including 11 patients with no evidence of
renal lesion, 17 patients with single glomerulomegaly, 21 patients with single podocyte
hypertrophy, 10 patients with glomerulomegaly and podocyte hypertrophy, 5 patients with
focal segmental hyalinosis, and 16 patients with increased mesangial matrix and/or mesan-
gial proliferation, participated in this study. Biological parameters, including serum IGF-1
concentrations with the standard deviation score for age (SDS-IGF-1), were determined for
all patients.
Results
Eighty patients (50 women and 30 men) with a mean BMI of 52.63 ± 8.71 and a mean age
of 42.40 ± 9.45 years were included in this study. IGF-1, IGF-1 SDS and IGF-1BP3 levels
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according to the renal injury were compared (normal glomeruli: IGF-1 = 190.17 ± 72.46; glo-
merulomegaly: IGF-1 = 122.3 ± 50.05; podocyte hypertrophy: IGF-1 = 119.81 ± 60.34; focal
segmental hyalinosis: IGF-1 170.98 ± 100.83, increased mesangial matrix and/or mesan-
gial proliferation: IGF-1 117.73 ± 63.87). Statistically significant differences were observed
between serum levels of IGF-1 and between the levels of SDS-IGF-1 by comparing the
group without glomerular lesion with the group formed by patients with any type of glomeru-
lar injury. Logistic regression analysis was performed, with the dependent variable defined
as the glomerular injury. In the multivariate analysis, only SDS-IGF-1 was associated with
glomerular injury, and low levels of IGF-1 SDS were a risk factor for kidney injury.
Conclusions
Our study demonstrates that low IGF-1 serum levels are associated with renal lesions in
morbidly obese patients without overt clinical renal manifestations.
Introduction
Insulin-like growth factor 1 (IGF-1) is a peptide hormone synthesized mainly by liver mesen-
chymal cells under the control of growth hormone (GH) and secreted into the blood. The
plasma IGF-1 concentrations depends primarily on the GH levels, nutritional status, and phys-
ical activity level [1,2]. IGF-1 promotes growth and differentiation in a variety of tissues and
also maintains structural integrity, inhibits apoptosis, and exerts anti-inflammatory effects.
Insulin like growth factor 1 deficiency has been linked to increased risks of stroke and ische-
mic heart disease [3,4]. Further, low serum IGF-1 concentrations have been consistently
observed in severely obese patients [5,6].
Insulin like growth factor 1 stimulates the kidney by increasing blood flow and the glomeru-
lar filtration rate (GFR) [7]. Many experimental animal studies have been performed to deter-
mine the effects of IGF-1 on renal function. However, the few human studies that have been
conducted have yielded conflicting results. The serum IGF-1 is lower in children with chronic
kidney disease (CKD) than in those with a normal GFR [8]. However, increases in the IGF-1
and IGF-1 binding protein 3 (IGFBP-3) levels have been observed in adult patients with a
decreased estimated GFR [9], and low IGF-1 have been reported in adult patients with CKD
and cachexia [10]. Obesity is a cause of CKD. We have previously reported the association of
several glomerular lesions (increased mesangial matrix, mesangial cell proliferation, podocyte
hypertrophy, glomerulomegaly, and focal and segmental glomerulosclerosis) with morbid obe-
sity in patients without overt clinical renal manifestations [11]. However, no studies have
investigated the IGF-1 level in morbidly obese patients and its association with renal lesions.
Our principal aim was to compare the serum IGF-1 concentrations in morbidly obese
patients with normal renal function with or without early obesity-related glomerular lesions.
We evaluated the association of the IGF-1 levels with the presence of different types of renal
lesions and with several biochemical parameters.
Material and Methods
We analyzed patients’ serum IGF-1 concentrations determined in a previous study performed
by our research group [11]. One hundred thirty morbidly obese patients with an unknown his-
tory of kidney disease who had undergone open bariatric surgery (and renal biopsy at surgery)
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at our hospital between December 2001 and November 2005 were invited to participate in the
study.
Of the 130 patients, 5 refused to participate, and 30 could not undergo renal biopsy or had
insufficient renal tissue available for histological analysis. The remaining 95 patients were
included in the previous study [11].
Of the 95 patients, 80 patients whose IGF-1 level was determined before bariatric surgery
were included in the current study.
None of the selected patients had a history of renal disease or was currently on insulin ther-
apy, oral antidiabetic treatment or lipid-lowering drugs. This study was approved by the ethics
committee of our hospital, and all patients signed informed consent forms.
Blood samples were drawn from fasting patients at baseline, before bariatric surgery. Serum
samples were kept frozen at -80°C until measurement of adiponectin (ADPN) concentrations.
Urine samples were collected from all patients during the previous 24 h period. Plasma glucose,
total cholesterol, triglyceride, creatinine and urinary creatinine levels were measured using a
Cobas1 711 Roche Diagnostics analyzer. Creatinine clearance was calculated using the follow-
ing equation: 24 h urine (ml) x urinary creatinine concentration x 1000 / (plasma creatinine
concentration x 1440 min). Proteinuria (24 h) was determined by a spectrophotometric
method (pyrogallol red) and albuminuria (24 h) was measured by nephelometry. Serum
ADPN concentrations were measured using a commercial radioimmunoassay (Linco Research
Inc., St Louis, MO). The intra-assay coefficient of variation (CV) was below 6.2%, and the
inter-assay CV was below 9.2%. High sensitivity C-reactive protein (HS-CRP) concentrations
were determined using an ultrasensitive CRP test (N HS-CRP; Dade Behrin Marburg GmbH,
Marburg, Germany), and the inter-assay CV was< 3.9%. The detection limit of the assay was
0.175 mg/L, and it was performed at a sample dilution of 1:20.
Serum total IGF-1 and IGFBP-3 levels were measured using a chemiluminescence immuno-
assay (Immulite 2000, Siemens Healthcare Diagnostics Products, UK). IGF-I was standardized
against the World Health Organization/National Institute for Biological Standards and Control
(WHO NIBSC) 1st IRR 87/518 (1 ng/ml x 0.13 = 1 nmol/L; the sensitivity was 20 ng/mL) and
the intra-assay and inter-assay CVs were< 3.9 and< 7.7%, respectively. IGFBP-3 was stan-
dardized against the WHO NIBSC Reagent 93/560 (1 μg/ml x 34.78 = 1 nmol/L). The sensitiv-
ity was 0.1 μg/mL, and the intra-assay and inter-assay CVs were< 4.6 and< 7.3%,
respectively. The IGF-I/IGFBP-3 ratio was calculated on a molar basis (IGF-I nmol/L/IGFBP-3
nmol/L).
Standard deviation scores (SDS) were calculated according to an age-related reference popu-
lation mean based on the data provided by the assay manufacturer for each IGF-1 level. Low
IGF-1 was defined as an IGF-1 SDS of below -2.
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters
squared. Waist circumference was measured at the approximate midpoint between the lower
margin of the last palpable rib and the top of the iliac crest. Blood pressure was determined
with a standard mercury sphygmomanometer cuff of suitable size. Hypertension was defined
as systolic blood pressure (SBP) 140 mmHg and/or diastolic blood pressure (DBP) 90
mmHg. The diagnostic criteria for diabetes was a fasting plasma glucose levels of 7.0 mmol/
L in two determinations and impaired fasting glucose, asdefined by a fasting serum glucose
level of 5.6 and<7 mmol/L. Hypercholesterolemia was defined as a total serum cholesterol
level of> 5.7; hypertriglyceridemia was defined as a triglyceride level of> 1.71 mmol/L. The
GFR was estimated according to creatinine clearance measured in a 24 h urine sample (without
correction for body surface area). Microalbuminuria was defined as the presence of 30 to 300
mg albumin in a 24 h urine sample and proteinuria was defined as the presence of> 300 mg
protein or albumin.
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The insulin resistance index was calculated using the homeostasis model assessment of insu-
lin resistance (HOMA-IR) as (fasting insulin mU/L) × (fasting glucose mmol/L) / 22.
Histological data
Renal biopsies were processed for histology as described in our previous study [11]. Glomeru-
lomegaly was defined as a glomerular area of above the mean glomerular area of a control
group plus two standard deviations. Podocyte hypertrophy was defined as podocyte enlarge-
ment with large nuclei and prominent nucleoli. Increased mesangial matrix was defined as
mesangial sclerosis resulting in widening of the mesangium. Mesangial cell proliferation was
defined as the presence of more than three mesangial cells surrounded by mesangial matrix in
an intact glomerular segment. Focal segmental hyalinosis was defined as focal and segmental
consolidation of the glomerular tuft by increased extracellular matrix, with obliteration of the
capillary lumina.
Each biopsy was assessed as described above, and the presence of one or several histological
lesions was registered.
Statistical analyses
The data were first tested for a normal distribution using the Kolmogorov-Smirnov test. Nor-
mally distributed variables were expressed as the mean ± SD. Nonparametric variables were
expressed as the median (25th and 75th percentiles). Associations of the IGF-1 level with the
clinical, anthropometric, biochemical and pathological data were identified using Pearson’s
correlation test, Student’s t-test and analysis of variance (ANOVA) as appropriate. Logistic
regression models were used to assess the associations of the IGF-1 level with the biochemical,
clinical and glomerular lesions.
All statistical analyses were conducted with SPSS statistical software package (version 15.0;
SPSS, Chicago, IL). Statistical significance was considered at a p<0.05.
Results
Clinical, anthropometric and biochemical data
The data are summarized in Table 1.
Fifty-three percent of the patients had arterial hypertension, 44% had hypercholesterolemia,
27% had hypertriglyceridemia. Twenty-one percent of patients exhibited impaired fasting glu-
cose, and 18.5% presented with a fasting plasma glucose level of higher than 7 mmol/L but
Table 1. Anthropometric and biochemical characteristics.
Age (years) 42.40 ± 9.45
Gender (F) 62.5%
BMI (kg/m2) 52.63 ± 8.71
Creatinine (mmol/L) 81.11 ± 12.36
Creatinine Clearence (mL/min) 135.96 ± 40.95
HOMA-IR (%) 5.19 ± 3.38
HS-CRP (mg/L) 9.84 (5.32–17.20)
ADPN (mcg/mL) 5.72 ± 3.05
Microalbuminuria (mg/24 h) 25.65 (8.30–92.55)
IGF-1 (ng/mL)) 134.15 ± 64.97
IGF-1 SDS 0.0006 (-1.52–0.77)
doi:10.1371/journal.pone.0154451.t001
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lower than 11 mmol/L in all cases. Only 4% exhibited a urinary albumin excretion rate of
higher than 300 mg/24 h but lower than 500 mg/24 h in all cases.
Histological data
Pathological examinations revealed no evidence of renal injury in 11 patients, and the presence
of renal lesion in 69 patients. Of the 69 patients, glomerulomegaly alone was found in 17
patients, podocyte hypertrophy alone in 21, glomerulomegaly and podocyte hypertrophy in 10,
focal segmental hyalinosis in 5, and increased mesangial matrix and/or mesangial proliferation
in 16.
Differences in clinical and biochemical data in extremely obese patients
with and without renal lesion
We analyzed the differences in age, BMI, the glucose level, blood pressure, creatinine clearance,
microalbuminuria, and insulin resistance between the groups with and without renal lesions
(Table 2) and found significant differences in age and BMI between the two groups.
Associations between IGF-1 and clinical, anthropometric and
biochemical data in extremely obese patients
According to the correlation analysis, IGF-1 levels are associated with age (r: -0,481,
p< 0.0001), insulin level (r: 0.272, p = 0.014), and creatinine clearance (r: 0.361, p = 0.001).
No significant associations were observed between the IGF-1 level and BMI, the glucose
level, the HOMA-IR value or the inflammatory parameters (HS-CRP and ADPN levels).
IGF-1 levels and IGF-1 SDS according to the type of obesity related
glomerular lesion
We consecutively compared the IGF-1 levels and IGF-1 SDS between the morbidly obese
patients without a renal lesion and those with any type obesity related glomerular lesion.
The serum IGF-1 levels and IGF-1 SDS were significantly decreased in patients with any
type of obesity related glomerular lesion (n = 69) compared with those without glomerular
lesions (n = 11) (Fig 1). No significant differences were found in the IGFBP-3 level between the
groups (with or without glomerular lesion).
Patients with a renal lesion of any type had a lower IGF-1 level than those without a renal
lesion (Table 3, Fig 2).
However, according to multivariate analysis, only a low IGF-1 SDS was associated with glo-
merular injury (Table 4).
Discussion
This is the first clinical study to demonstrate that a low IGF-1 level is associated with renal
lesions in morbidly obese patients without clinical renal manifestations.
In our study, the serum IGF-1 level was found to be associated with age, the insulin level,
and the creatinine clearance. The age-dependency of IGF-1 is well known; a negative correla-
tion between the circulating IGF-1 level and age has been reported in previous studies [12,13].
Similar to our findings, a study of obese and insulin-resistant subjects has revealed a significant
correlation between the IGF-1 level and GFR [14], however no data have been reported on glo-
merular lesions in this study.
The etiology of decreased IGF-1 in obese patients is thought to be multifactorial.
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An increase in the IGF-1 level after weight loss has been demonstrated, suggesting that obe-
sity-related IGF-1 deficiency is an acquired condition [15]. A low serum IGF-1 level may indi-
cate its reduced production, and, notably, obese patients exhibit decreased GH secretion [16].
Insulin resistance is a well-known feature of obesity, and a low plasma IGF-1 concentration
has been reported to be significantly associated with insulin sensitivity [17]. Obesity represents
a state of chronic inflammation, and inflammation has been suggested to be related to renal
lesions in extremely obese patients [18].
In addition, the IGF and inflammatory systems are closely linked; an inverse association
between CRP and IGF has been previously demonstrated [19].
In our study morbidly obese patients with renal lesions had a lower IGF-1 level than those
without renal lesions. Furthermore IGF-1 level was lower in the groups of patients with differ-
ent types of obesity related glomerular lesion when comparing with those without renal lesion.
The physiological link between an obesity-related low IGF-1 level and the presence of renal
lesions is not completely understood; however, it is widely accepted that kidney disease influ-
ences the IGF/GH axis [20,21]. Renal IGF-1 has been shown to originate from circulating and
locally synthesized IGF-1, although locally produced renal IGF-1 has been shown to have no
significant effect on kidney growth [22]. IGF-1 inhibits podocyte and mesangial cell apoptosis
Table 2. Baseline characteristics of the groups with and without renal lesions.
Variable Without renal lesion (n = 11) With renal lesion (n = 69) p value
Age 36.55±10.43 43.33±9.02 0.026
BMI 47.71±4.62 53.38±8.98 0.05
SBP 134.73±10.99 140.67±18.03 0.29
DBP 82.18±9.81 81.81±13.38 0.9
Glucose 5.55±1.17 5.96±1.71 0.45
HOMA-IR 5.1±3.38 5.2±3.42 0.94
Creatinine clearance 158.200±57.58 132.41±36.99 0.17
Microalbuminuria 52.41±7.91 73.35±11.9 0.54
doi:10.1371/journal.pone.0154451.t002
Fig 1. IGF-1 levels in patients with and without renal lesion. IGF-1 levels and IGF-1 SDS in patients
without renal lesions were significantly different from patients (with n > 10) with different types of obesity
related glomerular lesion.
doi:10.1371/journal.pone.0154451.g001
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[23], and it is a potent mitogen for glomerular mesangial cells [24,25]. Growth hormone and
IGF-1 deficiencies have been associated with decreases in glomerular filtration and renal
plasma flow [26], although IGF-1 also seems to have GH-independent renal activity [27]. Ani-
mal studies have demonstrated generalized organ hypoplasia in IGF-1-deficient mice [28]. Fur-
ther, decreased IGF-1 levels have been reported in diabetic [29], end-stage renal disease and
hemodialysis patients [30,31].
In the recent literature, a role of IGF-1 as a therapeutic agent has also been discussed [32].
In animal studies, IGF-1 overexpression has been shown to improve the therapeutic action of
mesenchymal stem cells against acute kidney injury [33]. In addition, prolonged treatment
with recombinant human (rh) IGF-1 has been demonstrated to increase kidney size in hypoph-
ysectomized rats [34], while treatment of humans with rh IGF-1 increases glomerular filtration
and kidney size and has specific anabolic effects on renal function, potentially delaying the
onset of end-stage renal disease [35–38]
Interestingly, our patients did not present renal failure. Thus, a low IGF-1 level may be an
early marker of the presence of occult renal lesions.
In our study, a lowIGF-1 SDS was associated with glomerular lesions in multivariate analy-
sis. Our results suggest that a low IGF-1 SDS may be a risk factor for the development of renal
lesion in extremely obese patients
A limitation of our study is the relatively small sample size. However, the characteristics of
the included patients (morbidly obese with normal renal function and early diagnosis by renal
biopsy performed during bariatric surgery) were unique; thus, it would have been very difficult
Table 3. IGF-1 levels and SDS in patients without renal lesions and in those with different types of lesions.
variable WRL (n = 11) GM (n = 17) GM, PH (n = 10) PH (n = 21) OL (n = 16) p value
IGF-1 190.17 ± 72.46 122.3 ±0.05 122.94 ± 52.08 119.81 ± 60.34 117.73 ± 63.87 0,016
SDS-IGF-1 0.49 (0.25–1.46) -0.05 (-1.54–0.85) -0.21 (-1.99–0.59) -1.32 (-2.28–0.416) -0,822 (-1,88–0,24) 0,071
WRL without renal lesion, GM glomerulomegaly, PH podocitary hypertrophy, OL other lesions
doi:10.1371/journal.pone.0154451.t003
Fig 2. IGF-1 levels in patients without renal lesion and with different types of renal. Univariate and
multivariate logistic regression models were used to analyze variables such as SBP, DBP, BMI, creatinine
clearance, glucose, HOMA-IR, HS-CRP, and ADPN in our study population. The presence of a glomerular
lesion was defined as the dependent variable. Univariate analysis revealed that the presence of a glomerular
lesion was associated with a low IGF-1 SDS and BMI.
doi:10.1371/journal.pone.0154451.g002
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to increase the sample size because renal biopsy is not clinically indicated in morbidly obese
patients with normal renal function, and open bariatric surgery is no longer performed on
these patients at our hospital.
Another limitation of our study was that our study group was limited to morbidly obese
patients; therefore, our results are not applicable to patients with other degrees of obesity.
Further studies are required to clarify the pathogenic mechanisms underlying the involve-
ment of IGF-1 in obesity-related nephropathy.
In conclusion, our findings demonstrate that a low IGF-1 serum level is associated to obesity
related glomerular lesion in morbidly obese patients.
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